Braidwell LP Invests $34.02 Million in Maze Therapeutics, Inc. $MAZE

Braidwell LP bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, HoldingsChannel reports. The institutional investor bought 1,140,040 shares of the company’s stock, valued at approximately $34,019,000. Maze Therapeutics accounts for about 1.3% of Braidwell LP’s investment portfolio, making the stock its 29th biggest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the second quarter worth $122,983,582. Alphabet Inc. purchased a new stake in shares of Maze Therapeutics in the second quarter valued at $41,435,000. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth about $133,502,907. Spruce Street Capital LP bought a new stake in shares of Maze Therapeutics in the 1st quarter worth about $5,970,000. Finally, Hhlr Advisors LTD. purchased a new position in shares of Maze Therapeutics during the 2nd quarter worth about $10,922,000.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of Maze Therapeutics stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 115,610 shares of company stock valued at $3,264,381. 5.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

MAZE has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Price Performance

Shares of MAZE opened at $26.72 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The company has a 50 day moving average price of $28.76 and a 200-day moving average price of $31.34. Maze Therapeutics, Inc. has a fifty-two week low of $14.16 and a fifty-two week high of $53.65. The stock has a market capitalization of $1.48 billion, a PE ratio of -10.60 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Equities analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.